ACHV — ACHIEVE LIFE SCIENCES, INC.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 949858 ·
Last close
$7.54
Market Cap
$775.88M
52W High
$8.64
52W Low
$2.62
ADV30
1,591,333
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -18,392,000 | -74,769,000 | 190,439,000 | 47,958,000 | 205,115,000 |
| Mar 2026 | 0 | — | -10,463,000 | -10,168,000 | 33,105,000 | 28,078,000 | 22,427,000 |
| Dec 2025 | 0 | — | -14,731,000 | -14,662,000 | 41,790,000 | 20,909,000 | 20,272,000 |
| Sep 2025 | 0 | — | -14,692,000 | -14,441,000 | 52,040,000 | 31,930,000 | 18,425,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-45,309,000
Investing CF
$9,034,000
Financing CF
$51,548,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.12
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-270,394,000
Inventory
—
Receivables
$0
ST Investments
$1,191,000
EBIT TTM
$-51,081,000
Pretax Income TTM
$-51,989,000
Interest Exp TTM
$908,000
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -54,880,000 | -54,648,000 | 41,790,000 | 20,272,000 | 21,518,000 | -49,465,000 |
| Dec 2024 | 0 | -39,069,000 | -39,827,000 | 38,633,000 | 17,734,000 | 20,899,000 | -29,770,000 |
| Dec 2023 | 0 | -27,250,000 | -29,815,000 | 19,371,000 | 20,819,000 | -1,448,000 | -24,479,000 |
| Dec 2022 | 0 | -40,800,000 | -42,350,000 | 29,971,000 | 21,668,000 | 8,303,000 | -37,569,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.64
Max Pain — expiry 2026-12-18
max pain strike: $5.00 · spot: $7.49 · call oi: 26,104 · put oi: 215
Expected Move to 2026-12-18:
±$2.50
(33.36%) —
implied range
$4.99 –
$9.99
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QDEL | QuidelOrtho Corp | $750.22M | $10.94 | — |
| OABI | OmniAb, Inc. | $670.25M | $4.61 | — |
| TKNO | Alpha Teknova, Inc. | $500.91M | $9.33 | — |
| NRC | NRC HEALTH | $432.88M | $19.57 | — |
| MYGN | MYRIAD GENETICS INC | $398.86M | $4.17 | — |
News headlines (Yahoo Finance, 1h cache)
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
2026-09-28 12:30 · Yahoo
ACHV: Looking Ahead to Resubmission
2026-08-18 10:21 · Yahoo
Achieve Life Sciences Stock Has Nearly Tripled in the Last Year. Now It Just Needs to Turn a Profit.
2026-08-12 17:10 · Yahoo
Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-11 12:30 · Yahoo
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
2026-07-31 12:30 · Yahoo
Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting
2026-07-10 00:01 · Yahoo
Achieve Life Sciences Joins Russell 2000® Index
2026-06-29 12:30 · Yahoo
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA
2026-06-22 12:30 · Yahoo
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
2026-06-02 12:30 · Yahoo
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
2026-05-19 18:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.